The Clinical Trials Support Resource (CTSR) provides infrastructure support for all aspects of clinical protocol research at MD Anderson. The services of this shared resource encompass submitting, activating, and closing single and multi-centered clinical trials;educating research staff on human subjects/clinical research;auditing and monitoring active clinical trials;and ensuring regulatory compliance of IND studies. The online data management system is maintained by the CTSR. The CTSR complements the activities of the Protocol Review and Monitoring System by supporting the electronic protocol submission and review processes, and the CTSR will manage the transition from the current electronic protocol management system to a new platform called """"""""eResearch,"""""""" which will """"""""go live"""""""" in early 2013. The CTSR is supported by 106 staff members (of which 8 full-time employees receive full or partial support from the CCSG) under the direction of Dr. Aman Buzdar, Vice President for Clinical Research Administration. During the past 5 years, the number of new protocols managed by CTSR has increased by 4% from 4,632 in fiscal year (FY) 2007 to 4,818 in FY 2011. Overall, trials led by MD Anderson investigators contributed to the FDA approval of 19 drugs for initial or new indications. New patient registrations have increased from 28,762 in FY 2007 to 46,262 in FY 2011, and the number of patients enrolled in therapeutic clinical trials has increased by 18%, from 6,219 in FY 2007 to 7,558 in FY 2011. During the last grant year, the funds used to support the CTSR salaries were $442,190 (9%) from the CCSG, $812,112 (16%) from user fees, and $3,742,322 (75%) from MD Anderson. In the next award cycle, the level of support from the CCSG, user fees, and MD Anderson is projected to be closer to 4%, 7%, and 89%, respectively. During this past 5-year funding period, CTSR resources were used by 934 principal investigators affiliated with all 19 CCSG programs. Peer reviewed investigators account for 61% of the utilization and 4% of total costs are requested from the CCSG. Publications cited using the CTSR have appeared in several high impact journals such as N Engl J Med and J Clin Oncol. Future plans include implementation of eResearch, which will serve as the new institutional clinical data enterprise system;coordination and modification of inter-departmental operational processes to further reduce time from submission to activation of clinical trials to 60 days;and further enhancements to the human subjects protection training programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759803
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$614,509
Indirect Cost
$230,601
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Taylor, Alison M; Shih, Juliann; Ha, Gavin et al. (2018) Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33:676-689.e3
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Jabbour, Elias; DerSarkissian, Maral; Duh, Mei Sheng et al. (2018) Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 18:257-265
Pataer, Apar; Shao, Ruping; Correa, Arlene M et al. (2018) Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med 7:2405-2414
Short, Nicholas J; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59:813-820
Shank, Brandon R; Deaver, Melissa; Baker, Angela et al. (2018) Interdisciplinary implementation of tacrolimus intravenous standard concentration in hematopoietic stem cell transplantation recipients. J Oncol Pharm Pract 24:365-370
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Lu, Zhongming; Sturgis, Erich M; Zhu, Lijun et al. (2018) Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 57:361-369
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103

Showing the most recent 10 out of 12418 publications